Ample evidence demonstrated that Adipolin/C1qdc2/CTRP12 and SFRP5 could regulate and improve glucose metabolism, inflammation level, insulin resistance (IR), and dyslipidemia. This evidence concerns the gene SFRP5 and metabolic syndrome.